BRIEF—Mestag Therapeutics and VIB ink exclusive partnership in oncology

UK breakthrough inflammatory disease and immuno-oncology company Mestag Therapeutics and VIB, the leading life science research institute in Flanders, today announced an agreement under which Mestag obtains the exclusive worldwide rights to research, develop and commercialize a panel of single domain antibodies, also known as Nanobodies, to an undisclosed target that plays a central role in anti-cancer immunity.

Mestag will be responsible for the research, development and commercialization of the antibodies, which are the outcome of many years of leading-edge research within VIB.

In return, VIB will receive an undisclosed upfront payment, future success-based milestones and royalty payments.